Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 42Cytarabine 33Methotrexate 31Vincristine 27Filgrastim 26Etoposide 24Radiotherapy 19Peripheral Blood Stem Cell Transplantation 18Dexamethasone 18fludarabine phosphate 16Leucovorin 16Mercaptopurine 15Asparaginase 15Daunorubicin 14Prednisone 13merphos 12Doxorubicin 12Cyclosporine 11pegaspargase 10Vorinostat 10Rituximab 10Busulfan 10tanespimycin 9Ifosfamide 9Bortezomib 9Methylprednisolone 8Hydrocortisone 8Calcium Dobesilate 8fludarabine 7Tacrolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Chromatography, High Pressure Liquid × Clear all
NCT01383447 2017-08-08

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Terminated
2 enrolled 4 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡